Why the FDA rejected a ‘breakthrough’ melanoma drug
For patients whose skin cancer doesn’t respond to traditional treatments, a new drug called RP1 has been a lifeline—at least for those who can get into a clinical trial. The drug has shown so much promise in such trials that, at the end of 2024, its development was placed on a fast track, with all…
